These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17889158)

  • 1. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V; Gutierrez C; Cabello M; Burgos D; Sola E; Gonzalez-Molina M
    Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus in renal transplant patients with tumors.
    Sánchez-Fructuoso A; Conesa J; Perez Flores I; Ridao N; Calvo N; Prats D; Rodríguez A; Barrientos A
    Transplant Proc; 2006 Oct; 38(8):2451-2. PubMed ID: 17097964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM; Sahin S; Kantarci G; Ergin H
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
    Gutiérrez-Dalmau A; Sánchez-Fructuoso A; Sanz-Guajardo A; Mazuecos A; Franco A; Rial MC; Iranzo P; Torregrosa JV; Oppenheimer F; Campistol JM
    Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
    Ruiz JC; Diekmann F; Campistol JM; Sanchez-Fructuoso A; Rivera C; Oliver J; Fernandez-Fresnedo G; Arias M
    Transplant Proc; 2005 Nov; 37(9):3833-5. PubMed ID: 16386555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Gonzalez Molina M; Hernandez D
    Transplant Proc; 2009; 41(6):2137-8. PubMed ID: 19715855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
    Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
    Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
    Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
    Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients.
    Martinez-Mier G; Avila-Pardo SF; Mendez-Lopez MT; Budar-Fernandez LF
    Clin Transplant; 2010; 24(4):467-73. PubMed ID: 19744089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus experience in heart transplantation.
    Aranda-Dios A; Lage E; Sobrino JM; Mogollón MV; Guisado A; Cabezón S; Hinojosa R; Hernández A; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.